The most common grade ≥ 3 treatment-related AEs were neutropenia (25% for monotherapy, 24% for combination therapy) and thrombocytopenia (23% for monotherapy, 22% for combination therapy).73 These phase 1 findings were the basis for the Brightline-2 phase 2a/b study (NCT05512377) of brigimadlin in patients with advanced, MDM2-amplified, TP53 wild-type BTC, pancreatic ductal adenocarcinoma, and other select solid tumors.49,74 This study has closed, and the brigimadlin development program across various oncology indications has been discontinued. Here, MDM2 is linked to neutropenia.